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Abstract
The objectives of this report are to review the assessment of patient-focused outcomes in pediatric orthopedic
surgery, to describe a framework for identifying appropriate sets of measures, and to illustrate an application of
the framework to a challenging orthopedic problem.
A detailed framework of study design and measurement factors is described. The factors are important for
selecting appropriate instruments to measure health status and health-related quality of life (HRQL) in a particular
context. A study to evaluate treatment alternatives for patients with neurofibromatosis type 1 and congenital
tibial dysplasia (NF1-CTD) provides a rich illustration of the application of the framework. The application
involves great variability in the instrument selection factors. Furthermore, these patients and their supportive
caregivers face numerous complex health challenges with long-term implications for HRQL.
Detailed summaries of important generic preference-based multi-attribute measurement systems, pediatric health
profile instruments, and pediatric orthopedic-specific instruments are presented. Age-appropriate generic and
specific measures are identified for study of NF1-CTD patients. Selected measures include the Activities Scale for
Children, Gillette Functional Assessment Questionnaire Walking Scale, Health Utilities Index, and Pediatric
Inventory of Quality of Life.
Reliable and valid measures for application to pediatric orthopedics are available. There are important differences
among measures. The selected measures complement each other. The framework in this report provides a guide
for selecting appropriate measures. Application of appropriate sets of measures will enhance the ability to
describe the morbidity of pediatric orthopedic patients and to assess the effectiveness of alternative clinical
interventions. The framework for measurement of health status and HRQL from a patient perspective has
relevance to many other areas of orthopedic practice.
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Review
Assessments of patient-focused health status and health-
related quality of life (HRQL) are being recognized
increasingly by clinicians, patient advocates, regulatory
authorities, administrators and policy makers as primary
measures of the need, efficacy, effectiveness and efficiency
associated with health care services. These types of meas-
ures are commonly reported in the published literature of
many health care disciplines although there are few pub-
lished reports concerning orthopedic surgery. However,
the orthopedic community is becoming interested in
using evidence reported by patients and patients' family
members to determine what is best for patients.
Patient-focused evidence (including patient-reported out-
comes, PROs) refers to results from functional health sta-
tus (FHS) and HRQL studies of orthopedic outcomes with
measurements obtained from the perspective of patients
or their non-clinician caregivers (e.g., parents of patients
too young to self-report). The field of orthopedics is con-
cerned with all musculo-skeletal problems from the top to
the bottom of the human body. This broad anatomical
range is associated with a wide range of functional prob-
lems. Some orthopedic problems are highly focused in
regards to anatomy and associated with highly effective
therapies. However, other orthopedic problems are of a
diverse nature, the etiology is often poorly understood,
and effective treatment strategies are sometimes elusive.
The breadth and depth of some particularly challenging
orthopedic problems has stimulated an interest in
patient-based perspectives of their own FHS and HRQL.
These types of measures will be referred to as "health
measures" for the purposes of this paper. Health measures
can be used to assess the burden of morbidity associated
with orthopedic diagnoses, and to assess the effectiveness
and efficiency of therapies. The diversity of issues also led
the American Academy of Orthopedic Surgeons and the
Pediatric Orthopedic Society of North America to develop
the Pediatric Outcomes Data Collection Instrument
(PODCI), and led other researchers to develop function-
specific instruments such as the Activities Scale for Kids
(ASK). However, there are a large variety of potentially
appropriate health measures and there are limits to the
number of these measures that can be used in any given
study. The most appropriate set of health measures should
be selected on the basis of underlying study objectives and
design criteria [1].
Objectives and designs vary greatly across orthopedic
studies. In general, orthopedic procedures and programs
are undertaken to improve the health of patients. The
health of patients can be measured in different ways. Con-
ventional clinical or physiological measures are generally
very useful for diagnostic and therapeutic purposes. Con-
ventional clinical measures may, however, provide an
incomplete assessment of health. For example, clinical
examination and gait measures have been used to
describe the quality and quantity of limitations in walking
ability associated with hip flexion contracture but these
types of assessments provide little information about the
importance of this contracture relative to that of other
serious health problems. In addition, various measures
may provide conflicting results: some indicating improve-
ment while others suggest decline in patients' health.
Therefore, in the interest of scientific rigor, protocols to
assess the overall effectiveness of therapy should include a
priori  specification of the comprehensive measure of
health and a credible assessment viewpoint for the pur-
poses of primary analysis of study results. Secondary study
objectives may involve use of data collected from other
health measures or from other assessment perspectives.
FHS and HRQL measures are important for a variety of
reasons that complement conventional clinical measures
[2]. FHS measures provide descriptive information and
HRQL measures add some type of valuation about the
desirability of overall health status. Valuation may be
based on preference-based scores or by including only
items identified as important to patients. HRQL is a more
comprehensive concept than FHS as noted in this leading
definition.
"Health-related quality of life is the value assigned to
duration of life as modified by the impairments, func-
tional states, perceptions, and social opportunities that
are influenced by disease, injury, treatment or policy" [3].
It is generally accepted that a goal of therapy is to make
patients feel better [4] and this is supported by statements
of leading policy analysts such as "The goal of health care
is to protect, promote, and maintain the health status of
people" [5] and "Since the ultimate goal of all health care
is to improve, restore, and preserve HRQL" [6]. However,
physiological measures may change without people feel-
ing better and people may feel better without measurable
change in physiological function. Furthermore there is
often a need for trade-offs between treatment-related ben-
efits and adverse side effects. There is an increasing aware-
ness also that various stakeholders in clinical decisions
often have differing opinions about disability and that the
opinions of patients should count. Numerous valid and
reliable questionnaires are now available to collect FHS
and HRQL measurements from patients and their repre-
sentatives. The measures may be used for discriminative
(comparing groups at a point in time such as assessing the
burden of illness), evaluative (assessing within-person
change over time as in clinical trials), and predictive pur-
poses (providing prognostic information) [7].Health and Quality of Life Outcomes 2005, 3:3 http://www.hqlo.com/content/3/1/3
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A series of studies from a randomized controlled clinical
trial (RCT) and prospective cohort study of elective total
hip arthroplasty are illustrative of these purposes. These
examples, while not from a pediatric setting, are ortho-
pedic and demonstrate how data can be used for a variety
of purposes. In the RCT, Rorabeck and colleagues [8]
undertook a discriminative analysis of a set of FHS and
HRQL measures, and reported there were no differences
in outcomes between cemented and non-cemented proth-
eses. Evaluative analyses of data from the same trial have
documented improvements according to six HRQL meas-
ures and the six-minute-walk test [9], and have shown
important differences among results from four major
generic HRQL measures [10]. In the prospective cohort
study by Mahon et al [11], waiting time for surgery was
inversely related to baseline WOMAC (Western Ontario
and McMaster University Osteoarthritis Index) scores for
patients at time of referral to an orthopedic surgeon.
There are many factors to consider when designing studies
using patient-focused health measures for orthopedic
patients. Among the most important factors are the study
objectives, types of patients, the dimensions and FHS con-
structs associated with the health problem under study,
the appropriateness of the questionnaire for the age range
of the patients, the viewpoint of the assessors answering
the questionnaire, the method of collecting questionnaire
information (self-completion or interviewer-administra-
tion), the period of time respondents are asked to con-
sider when answering the questionnaire (i.e., assessment
recall period), and measurement properties of assessment
tools. Measurement properties include content and con-
struct validity, test-retest and inter-rater reliability, respon-
siveness, and practical limitations of data collection. It
takes many years, and often decades, for credible and rel-
evant evidence to be accumulated about the measurement
properties of instruments. Instruments with well-estab-
lished measurement properties should be used whenever
possible. Two prime issues for assessments of children are
the developmental stage of the subjects and the most
appropriate respondent for questionnaires.
The methods section of the paper presents a framework of
important factors for consideration in designing studies to
assess FHS and HRQL for orthopedic patients. The results
were generated by applying the framework in the context
of developing a proposal for a comprehensive interna-
tional study of patients with neurofibromatosis type 1
(NF1) and congenital tibial dysplasia (CTD). The NF1-
CTD protocol provides a rich illustration because it
encompasses great variability in the instrument selection
factors, and these patients with their supportive caregivers
face numerous complex health status challenges with
long-term implications for HRQL. Furthermore, there is
little information in the published literature about the
comprehensive health status and HRQL of patients with
NF1-CTD. The rationale and approach to studying FHS
and HRQL from a patient perspective have relevance to
many other areas of orthopedics.
Methods: a framework for orthopedic 
applications
This section identifies specific study design and measure-
ment instrument factors that should be considered in
selecting measures for use in studies, and presents some
background information for illustrating the application of
these factors.
Study design factors
Study design factors are specified in detailed protocols
that clearly define the study objectives and conditions.
Well-defined study objectives identify the study subjects,
and type and number of measurements required. Study
conditions describe practical issues including data collec-
tion sites, and budgets for time and resources.
Variability in study objectives
A highly focused, single objective study may require rela-
tively few instruments while a broad-based, multi-faceted
study will require numerous measures. For example, a
RCT of efficacy for an experimental technique to achieve
union of bone compared to a conventional technique
might specify patients' reports from a single well-estab-
lished walking ability scale as the primary outcome meas-
ure. However, an economic evaluation of the cost-
effectiveness and cost-utility of the experimental tech-
nique would require at least two instruments: the single
well-established walking ability scale to estimate effective-
ness for the numerator in the cost-effectiveness ratio; and
a utility-based scale of overall HRQL to estimate quality-
adjusted life years for the numerator in the cost-utility
ratio.
Age range of subjects
The age of study subjects affects the choice of measure-
ment instruments and the method of collecting data. Each
instrument is valid for a specific age range and the age
range is quite small for many pediatric instruments. For
example, developmental changes during childhood make
it difficult for single instruments to be valid from infancy
through adolescence. Many instruments are valid for one
or more of the following age categories: infants, pre-
school children, primary-school children, adolescents,
young / middle-age adults, seniors and elderly. Inability
to read well (e.g., young children or populations with
high illiteracy rates), or see well (e.g., many elderly popu-
lations), or concentrate well (e.g., people on certain
strong medications) inhibits use of self-complete ques-
tions. Well-designed interviewer-administered question-
naires pose clear, short, well-focused questions withHealth and Quality of Life Outcomes 2005, 3:3 http://www.hqlo.com/content/3/1/3
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readily understood and easily remembered response
options (e.g., yes or no response options).
Assessment perspective
It is becoming widely accepted in many disciplines that
studies of health care programs and technologies should
include measures of patients' perceptions of their FHS and
HRQL [12]. Measurements of these types have been
shown to vary by assessment viewpoint and, although
many different viewpoints are valid, the patient perspec-
tive is considered to be one of the most important. It has
been shown that children as young as 7 years can reliably
complete interviewer-administered disease-specific and
generic questionnaires about their own health [13].
Type of data collection sites
The locations and cultural characteristics of the study pop-
ulation will determine the language and sometimes the
choice of assessors. Relatively few instruments have been
carefully translated and culturally-adapted to facilitate use
in a large variety of communities. Some cultures accept a
variety of assessment viewpoints (e.g., patient, family,
nurse, physician, and other allied health professionals)
while other cultures recognize only a physician viewpoint
for health assessments.
Mode of data collection
The literature suggests that there may be important effects
due to mode of data collection [14] and, therefore, mode
of administration should be standardized across subjects,
assessors, and assessment points. In general, self-complete
questionnaires tend to elicit reports of greater morbidity
than interviewer-administered questionnaires. It is
hypothesized that subjects may be less inhibited to report
disabilities on self-complete questionnaires than to report
disabilities to interviewers. The mode of data collection
for a study may be determined by numerous factors other
than the characteristics of study subjects mentioned
above. A low budget study may rely on a mail survey, or
distribution of questionnaires in a busy clinic setting, and
use self-complete questionnaires. Alternatively, a study
involving serial assessments may require follow-up data
to be collected by telephone and therefore require use of
questionnaires designed for interviewer-administration.
Assessment recall period
FHS questionnaires should have well-specified assess-
ment periods to help ensure that the subjects and
researchers know the period of time covered by the
responses. Assessment recall period refers to the period of
time the assessor is asked to consider when answering the
questionnaire. The period should match the objectives of
the study. For instance, if a new surgical technique is
thought to reduce the peri-operative burden of morbidity
then frequent assessments with a brief recall period (24
hours) might be suitable. Standard assessment periods
include the past 24 hours, the past 1 week, the past 2
weeks and the past 4 weeks. Short assessment periods
should be used in studies of patients whose FHS varies
over time and in studies involving serial assessments to
ensure that there is no overlap in assessment times. Rela-
tively long recall assessment durations may be used when
it can be assumed patients' health status is fairly stable.
For example, a four-week recall assessment period was
used to measure the HRQL of patients in a randomized
clinical trial and economic evaluation of two alternative
treatment strategies for patients with knee osteoarthritis
[15,16].
Other factors
There are limits to the number and type of measures that
respondents can be expected to complete without getting
tired or frustrated, and/or that the study budget can afford
in regards to both data collection and analysis. The evi-
dence about the limits of respondent burden is sparse. All
else being equal, studies involving serial assessments
should expect to collect fewer measurements per assess-
ment than single-assessment cross-sectional surveys. To
maximize efficiency, instruments should be selected to
provide complementary rather than overlapping
information.
Instrument factors
Types of measures
There are numerous definitions of FHS and HRQL. For the
purposes of the paper, a FHS measure is defined as being
descriptive in terms of functional ability and HRQL is
defined as involving some form of valuation of that health
status.
One published taxonomy [7] suggests that measures may
be classified as specific or generic. Specific measures are
focused on a specified health problem, disease, or age
group of subjects. An example is the Western Ontario
McMaster Osteoarthritis Index [17]. Specific measures
designed for evaluative purposes are often able to detect
small but clinically important differences among subjects
and be responsive to small but clinically important intra-
subject changes over time. Generic measures are applica-
ble to a broad range of subjects, including a wide variety
of clinical groups and general populations. There are 2
types of generic measures: generic health profile instru-
ments such as the Rand-36 [18] and SF-36 [19]; and
generic preference-based instruments. There are 2 types of
generic preference-based instruments: direct measure-
ment instruments, such as standard gamble [20]; and
multi-attribute classification systems with preference-
based scoring functions [21], such as the Health Utilities
Index [22,23] and the Quality of Well-Being Scale [24,25].
A detailed description of direct measurement techniquesHealth and Quality of Life Outcomes 2005, 3:3 http://www.hqlo.com/content/3/1/3
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is beyond the scope of this paper but provided in a recent
review paper by Torrance and colleagues [20]. Direct pref-
erence measurement is generally not practical for applica-
tion in most clinical studies, especially those involving
very young children. Customized instrumentation, usu-
ally relying on administration by highly skilled interview-
ers, must be developed for each study. Further,
measurement questions are cognitively demanding.
Direct preference measurement will, therefore, not be
considered further in this paper.
Each multi-attribute system includes a descriptive classifi-
cation scheme to describe and assess health status, and a
preference-based valuation system. HRQL scores for
health states defined by multi-attribute systems are calcu-
lated from models fitted from directly measured prefer-
ence measurements (see below). Multi-attribute systems
provide descriptive information about comprehensive
health status, and interval-scale preference scores of over-
all HRQL from a community perspective on a scale where
0.00 is the score for being dead and 1.00 is the score for
being in perfect health. Several multi-attribute systems
define negative scores of overall HRQL to represent pref-
erences for states considered worse than being dead. A few
systems include single-attribute preference-based scales of
morbidity. Single-attribute morbidity scales are defined
such that the least desirable level within an attribute
(dimension of health status such as vision) has a score of
0.00 (blind) and the most desirable level has a score of
1.00. The community perspective is most widely recom-
mended for technology assessment and reference case
economic evaluation analyses [26-29]. Interval-scale
properties, and a score of 0.00 for being dead, are impor-
tant features of HRQL scales for integrating the effects of
morbidity and mortality in descriptive studies and in cost-
utility economic evaluations. Interval-scale preference
scores of HRQL may be either utilities (e.g., Health Utili-
ties Index Mark 3) or values (e.g., EQ-5D). Utility prefer-
ence measures are based on von Neumann-Morgenstern
utility theory, include an element of risk attitude, and are
therefore appropriate for decision problems with uncer-
tainty. Value scores are preferences measured under cer-
tainty. Details about differences between utilities and
values, and about direct preference measurement, appear
in recent papers by Torrance et al [20,30]. Uncertainty is
an important factor in many orthopedic procedures and
therefore utility scores are more appropriate than value
scores in this context.
Evidence of measurement properties: validity, reliability, 
and responsiveness
A valid measure is "sound and sufficient" [31]. There are
many ways to assess validity of measures. Assessments of
FHS and HRQL measures should consider at least six types
of validity: face validity, content validity, construct valid-
ity, convergent validity, discriminative validity, and pre-
dictive validity [32]. Face validity requires that a measure
appear on the surface to make sense in regards to being
relevant and useful. Content validity requires that the
measure include all important and relevant domains or
dimensions of health status. Construct validity describes
the extent to which a measure corresponds to theoretical
concepts and convergent validity describes the association
between related variables. Discriminant validity is a lack
of correlation between dissimilar variables or groups. Pre-
dictive validity, one type of criterion validity, describes the
relationship between current and future measurements.
A measure is reliable if it is sound and dependable [31].
Reliability is assessed by tests of repeatability or reproduc-
ibility. Reliability is often assessed in terms of agreement
between intra-subject test-retest measurements and inter-
assessor measurements [33].
Responsiveness is also referred to as sensitivity to change.
It is an important feature for determining a measure's abil-
ity to detect effects of treatments or natural changes over
time (e.g., due to the aging process). Husted and col-
leagues reviewed the literature and defined two major
types of responsiveness: internal and external responsive-
ness [34]. Internal responsiveness describes the ability of
a measure (instrument) to change and has been assessed
using a variety of techniques including the magnitude of
statistical significance tests (e.g., p < 0.05 versus p <
0.001), the mean change score divided by the standard
deviation of scores at baseline (effect size), and a sensitiv-
ity coefficient calculated as the proportion of the variance
in change scores due to treatment [32]. It has also been
assessed as the ratio of the mean change in patients' scores
and the pooled standard deviation of the mean change
scores [35], and as the mean change score among those
who changed divided by the standard deviation of change
scores among stable patients [33]. External responsiveness
is concerned with the relationship between change in a
measurement and change in a reference measurement of
health status. External responsiveness has been assessed
using the receiver operating characteristic method, corre-
lations (e.g., Pearson product moment correlation), and
regression models. The minimum important difference
(MID) is the smallest size of difference that is important
from patients' or clinicians' perspectives. The MID
between two measurements is a concept closely related to
responsiveness when assessing change over time [36].
Ceiling and floor effects are undesirable properties that
reduce the validity, reliability, and responsiveness of
measures. A ceiling effect may occur when a large propor-
tion of measurement observations are close to the upper
bound of the measurement scale. A ceiling effect results in
a positively skewed distribution of measurements, limitedHealth and Quality of Life Outcomes 2005, 3:3 http://www.hqlo.com/content/3/1/3
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ability of the measure to discriminate among subjects at
the upper end of the scale, and attenuated responsiveness
to improvements in health in longitudinal studies. A floor
effect may occur when a large proportion of measurement
observations are close to the lower bound of the measure-
ment scale. Floor effects create a negatively skewed distri-
bution of measurements, limited ability of the measure to
discriminate among subjects at the lower end of the scale,
and decreased responsiveness to decrements in health in
longitudinal studies. Many generic and specific measures
of HRQL may be subject to ceiling effect problems in that
they may not be able to describe patients or subjects with
above average (supra-normal) health. Some measures are
subject to floor effect problems. Some are subject to both.
Typically floor effect problems are more serious in clinical
studies (which often involve patients with disabilities)
and ceiling effect problems may be more problematic in
general population studies.
Limits of respondent burden
The limits of respondent burden depend upon many fac-
tors including the number of questions presented, how
the questions are presented, the complexity of questions,
the sophistication of respondents, and the respondents'
interest in the questions. In general, the allowable length
of questionnaire is shorter for mail and phone adminis-
tration than for face-to-face interviewer administration
[37]. One set of guidelines specifies the following maxi-
mum lengths: 20 questions for phone surveys; 60 ques-
tions for mailed surveys; and 80 questions for face-to-face
interview surveys [38]. Another guideline recommends
that telephone interviews not exceed 5 to 10 minutes [39].
These guidelines are in general agreement with maximum
recommended number of pages for self-administered
questionnaires: 2 to 4 page upper limit for topics not espe-
cially salient [40]; 12 page upper limit for self-adminis-
tered questionnaires [41]; and 4 to 6 page upper limit for
mailed surveys [42]. For mail-out surveys, the evidence
suggests no effect of length on response rates for question-
naires varying from 3 to 9 pages [43,44] but reduced
response rates with questionnaires greater than 12 pages
[41].
Availability of support services
Applications of FHS and HRQL measures are greatly facil-
itated by expert advice, detailed instructions and other
services designed to support users of a measure. Support-
ing documentation is usually protected by copyright and
should not be used without written permission of the
original developers. Documentation obtained from third-
party sources should be considered suspect because it is
frequently invalid. Licensing fees are used to fund high
quality, readily accessible service centers. Permission to
use copyright materials is typically granted one study at a
time. Support services may also include consultation
about the most appropriate versions of questionnaires for
use in a specific study. Application packages may include
data collection instruments such as questionnaires, proce-
dure manuals, coding algorithms and scoring systems, as
well as background information about the conceptual and
measurement properties of the instrument.
NF1-CTD: A case study
Recently there has been interest in using measures of FHS
and HRQL to evaluate treatment alternatives for NF1-
CTD. NF1 is one of the most common genetic disorders in
childhood [45]. It is estimated that at least 1 million peo-
ple throughout the world have NF1 [46]. NF1 has a wide
range of clinical manifestations including abnormalities
of the skin, nervous system, bones and soft tissues [46].
Other conditions experienced by children with NF1
include short stature and neurologic problems such as
learning disabilities or unspecified school performance
problems (36%), frequent headaches (28%), mental
retardation (6%), and reduced reproductive potential [46-
49].
CTD is rare in the general population, approximately 1
per 140,000 [46]. It has been estimated that approxi-
mately 1% of people with NF1 have CTD [46]. CTD is
diagnosed usually during the first year of life and fractures
often occur before 3 years of age. Frequently, initial pres-
entation is tibial bowing followed by subsequent fracture
and pseudoarthrosis [45]. There is no generally accepted
standard for management of CTD although most sur-
geons would suggest initial treatment of either intramed-
ullary fixation with bone grafting or resection and bone
transplant. Surgical procedures for the treatment of CTD
are fraught with complications and failure of union. For
the treatment of CTD, pre-fracture bracing until skeletal
maturity may be a better alternative than surgery. CTD is
associated with severe complications due to nonunion or
pseudoarthrosis after osteotomy and amputation may be
required.
Conventional clinical measures of CTD include the Craw-
ford classification system [46]. These measures provide
clinicians with important information used in diagnosis
and management of well-established symptoms. A list of
important concerns could be prepared by interviewing
patients and members of their families. Standardized
comprehensive tools that integrate multi-dimensional
effects would also be useful in quantifying the number
and extent of problems experienced by NF1-CTD patients,
and other pediatric orthopedic patients with complex
issues. The published literature on NF1 and NF1-CTD
contains virtually no information based on FHS or HRQL
measurements. The exception is a recent paper by
Wolkenstein and colleagues [50] who reported results
from 128 adult patients in France using the generic healthHealth and Quality of Life Outcomes 2005, 3:3 http://www.hqlo.com/content/3/1/3
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profile SF-36 and a skin-disease-specific measure,
Skindex-France.
Surveys of the published literature, experts in the fields,
web sites and other sources of information were con-
ducted to determine the dimensions of health that are
affected by NF1-CTD, the types of FHS and HRQL meas-
ures that have been used, which measures should be con-
sidered as potentially useful for studies of NF1-CTD, the
measurement properties of potentially useful measures,
and the relative merits of various measures. A review of
the on-line Quality of Life Instruments Database
(QOLID) developed by Dr. Marcello Tamburini and the
MAPI Research Institute [51], and correspondence with
instrument developers, identified a short list of poten-
tially useful measurement tools in each of the following
categories: generic preference-based HRQL systems, major
pediatric and other generic health profiles, and disease or
function specific measures. Selected measures should
have demonstrated properties in accordance with cur-
rently accepted criteria [12,52,53] and should provide
commensurate measurements for patients across a wide
age range. Problems with mobility, cognition, pain, emo-
tion (including impacts of problems with self-image),
self-care, vision, and fertility are aspects of health reported
in the published literature to be compromised in NF1
patients.
Illustrative study design criteria
There are five important research objectives of an NF1-
CTD study that provide a context for applying the frame-
work described in the Methods section:
1) to document long-term health outcomes associated
with the disease and its treatment;
2) to measure the burden of disease and treatment during
active therapy;
3) to investigate the hypothesis that improved HRQL is
associated with initial amputation compared with multi-
ple limb-saving procedures;
4) to determine relationships of FHS and HRQL with con-
ventional clinical variables used in diagnosis and manage-
ment; and
5) to assess the measurement properties (e.g., construct
validity, patient versus parent inter-rater reliability, and
responsiveness to change) of selected FHS and HRQL
measures in NF1-CTD patients.
These detailed objectives require the identification and
assessment of leading FHS and HRQL measures for use in
both cross-sectional and prospective longitudinal surveys.
The prevalence of NF1-CTD is relatively low. Patients will
need to be recruited from numerous clinical centers in
North America to generate precise estimates of FHS and
HRQL. Questionnaires should be available in at least 3
major languages: English, French and Spanish. The survey
population ranges in age from newborn into adulthood
and linking results across the study objectives requires
that at least some of the assessment tools be in common
across the age range of study patients. To avoid potential
confounding effects, data collection techniques should be
consistent across subjects and measures.
The patient-focus will be represented by collecting meas-
urements from all patients old enough to provide self-
assessments, and from parents acting as proxy assessors
for all children and adolescents. Self-complete question-
naires requiring minimal supervision should be used to
eliminate the need for interviewers at each clinical center,
to facilitate use of mail-out surveys, and to avoid potential
"interviewer" effects. The number and type of measures
per assessment, and the number of serial assessments per
patient, should be sufficient to address all the study objec-
tives within the limits of study resources and assessor bur-
den. Measures of morbidity associated with NF1-CTD
should be comparable with data on norms from surveys
of general populations and other patient groups, and be
useful for assessing the effectiveness and efficiency of
health care services.
Existing patient-focused health measures
The HRQL measure should be comprehensive and prefer-
ence-based, to facilitate a broad variety of comparisons. A
pediatric health profile measure and other specific meas-
ures will be selected to complement the selected prefer-
ence-based HRQL measure. FHS measures may be focused
on one or more of the following: the population of inter-
est (e.g., pediatrics); the major underlying disease (e.g.,
NF1); the major human function of most interest (e.g.,
walking ability); the medically-defined health problem of
most interest (e.g., tibial dysplasia); the medical speciality
most involved with treatment of the health problem (e.g.,
pediatric orthopedics).
There are six major generic preference-based HRQL utility
systems [21], presented here in chronological order of
development: QWB [25], 15D [54], HUI [23], EQ-5D
[55], AQOL [56] and SF-6D [57,58]. HRQL scores from
these systems represent mean community preference
scores. The 15D and AQOL have not been widely used
outside of Finland and Australia respectively and, there-
fore, will not be described further in this paper. The SF-6D
has been developed only recently so there is as yet little
evidence to report. The major features of QWB, HUI, EQ-
5D, and SF-6D systems are summarized in Table
1[21,25,57,59,60]. The major characteristics vary greatlyHealth and Quality of Life Outcomes 2005, 3:3 http://www.hqlo.com/content/3/1/3
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among the systems. For example, linear additive scoring
models do not include effects of preference interactions
among attributes or domains but multiplicative scoring
functions include these effects. The QWB is available in
both self-complete and interviewer-administered formats
[61]. The symptoms attribute is a dominant feature of the
QWB health status classification system. This emphasis is
reflected in the population-derived preference weights.
HUI health status classification systems cover more than
10 attributes. There is evidence that HUI scores agree well
with mean directly measured standard gamble utility
scores from a representative sample of the general popu-
lation [59,60,62,63]. Numerous versions of HUI ques-
tionnaires are available and HUI has a service center [64-
66]. It is available in numerous languages. A closely-
related comprehensive health status classification system
for pre-school children (CHSCS-PS) has been developed
recently [67-69] for children age 2 through 5 years of age.
EQ-5D is very simple and concise. It consists of 5
attributes with 3 levels per attribute, assesses "current"
health status, has been used in a large number of studies,
and is available in numerous languages. Information,
including a long list of references, about EQ-5D is availa-
ble on the EuroQol Group web site [70]. SF-6D is a multi-
attribute health status classification system based on the
SF-36 [19,71,72]. The SF-36 was not designed to be com-
mensurate with the fitting of a multi-attribute utility func-
tion. The SF-6D health status classification system is a sub-
set of the attributes defined in the SF-36 health status clas-
sification system [57]. SF-6D utility scores may be useful
in retrospective studies analyzing previously collected SF-
36 data.
The major population-specific health profiles include the
Child Health Questionnaire (CHQ), Pediatric Inventory
of Quality of Life (PedsQL), Pediatric Evaluation of Disa-
bility Inventory (PEI) and TNO-AZL Pre-School Children
Quality of Life questionnaire (TAPQOL). The PEI is lim-
ited to children age 0.5 – 7 years of age and requires a
structured parent interview or clinician observation [73].
TAPQOL [74,51] is limited to children 0.5 to 5 years of
age. Therefore, PEI and TAPQOL will not be discussed
further.
The major pediatric disease-/function-/specialty-specific
instruments include the PODCI (also referred to as the
POSNA or Pediatric Orthopedic Society of North America
instrument), ASK, Gillette Functional Assessment Ques-
tionnaire Walking Scale (FAQ walking scale), and Wee-
FIM. Wee-FIM [75], a popular measure of functional inde-
pendence, is not being considered because it involves cli-
nician assessments rather than assessments from a patient
or parent perspective. In general, disease-specific scales in
orthopedics focus on pain and physical function because
these factors are major areas of concern for orthopedic
patients and no generic health measures have been
developed specifically for orthopedic application [73]. No
relevant disease-specific measures or disease-specific pref-
erence-based tools were identified.
A summary of the major pediatric generic health profiles
appears in Tables 2 and 3. The CHQ [76] covers relevant
physical domains and provides detail on emotion/psy-
chological health. The PedsQL [77] assesses physical,
emotional, social and school functioning. It has demon-
Table 1: Major Characteristics of Five Generic Preference-Based Multi-Attribute Systems
Instrument QWB HUI EQ-5D SF-6D
HUI2 HUI3
Developed 1970s 1980s 1990s 1990s 1990s
# Attributes (# levels per 
attribute)
4 (3 to 27) 7 (3 to 5) 8 (5 or 6) 5 (3) 6* (4 to 6)
# of unique health states 1215 24000 972000 243 18000
Attributes Mobility, Physical 
activity, Social 
activity, Symptoms 
/ problems.
Sensation, Mobility, 
Emotion, Cognition,
Self-care,
Pain, Fertility.
Vision, Hearing, 
Speech, Ambulation, 
Dexterity, Emotion, 
Cognition, Pain.
Mobility, Self-care, 
Usual activities, Pain / 
discomfort, Anxiety / 
depression.
Physical functioning, 
Role limitations, Social 
functioning, Pain, 
Mental health, Vitality.
Types of HRQL scores 
and measurement
Values; VAS Utilities; VAS and 
SG combination
Utilities; VAS and 
SG combination
Values; TTO Utilities; SG
HRQL scoring model 
form
Linear additive Multiplicative Multiplicative Modified linear 
additive
Modified linear 
additive
HRQL scale interval 0.00 to 1.00 -0.03 to 1.00 -0.36 to 1.00 -0.59 to 1.00 0.00 to 1.00
Questionnaire formats 
(languages)
2 (numerous) 16 (numerous) 1 (numerous) 2 SF-36 versions 
(numerous)
SG – standard gamble; TTO – time trade-off; VAS – visual analog scale.
* – 6 attributes but role limitations attribute above includes emotional and physical so encompasses 7 of 8 SF-36 domains.Health and Quality of Life Outcomes 2005, 3:3 http://www.hqlo.com/content/3/1/3
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strated a return to health 3 months after acute limb frac-
tures [78] and has been used in large general population
surveys [79].
Table 4 summarizes the major characteristics of four
orthopedic-specific measures. The PODCI [80] was
designed specifically as a very comprehensive measure of
musclo-skeletal outcomes associated with pediatric
orthopedic problems. ASK was designed to measure chil-
dren's activities in terms of both capacity and perform-
ance [81], and it assesses domains not covered in detail by
other instruments [82]. The FAQ walking scale provides
the most complete measure of walking abilities.
The choice of existing measures is based on a process of
elimination considering the relative strengths of each
instrument and the complementarities among measures.
Neither the SF-36 nor the EQ-5D is valid for use in adoles-
cent patients with orthopedic problems [83]. A review of
measurement of HRQL in children by Eiser & Morse [[84];
see also [85,86]] identified HUI and CHQ and PedsQL as
the only 3 generic measures that fulfill all specified review
criteria: established reliability and validity; suitable for
self- and proxy-report; and brief (<30 items). PODCI out-
performed CHQ physical functioning scale for orthopedic
patients [87]. However, PODCI has considerable prob-
lems with missing data, especially in upper extremity
function and physical function and sports scales for chil-
dren ages 2 to 5 years, associated with the use of "too
young" response options [88]. ASK is reported to be more
sensitive to change in disability levels than HUI [Young N,
personal email communication to W Furlong 2002-02-
Table 2: Major Characteristics of Two Pediatric Health Profile Systems
Instrument CHQ PedsQL 4.0
Full Name Child Health Questionnaire Pediatric Inventory of Quality of Life
Origin 1996 1998
Version Parent Forms (PF) Parent Form for 
Infants & Toddlers
Youth- Completion 
Form
Child Self-Report 
Forms
1) ages 5–7 years
2) ages 8–12 years
3) ages 13–18 years
Parent Report Forms
1) ages 2–4 years
2) ages 5–7 years
3) ages 8–12 years
4) ages 13–18 years
Measurement 
Constructs
Measures of physical and psycho-social health concepts Measures of core dimensions delineated by 
WHO
Age Bounds (years) 5 to 17 2 months to 5 years 11 to 17 5 to 18 2 to 18
# Items 98 (PF98) or 50 
(PF50) or 28 (PF28) 
short form
102 87 (working on 
shorter form)
23
# Domains 10 child & 4 parent 
concepts
8 infant & 5 parent 
concepts
10 child concepts 4 "Generic Core"
Overall Score 2 Global Physical & Global Psycho-Social 1 overall, for primary analyses
Sub-scale Scores 14 13 10 4 sub-scales, for secondary and descriptive 
analyses
Completion Time 
(minutes)
10 to 20 for PF50;
7 to 15 for PF28
20 to 30 15 to 30 n/a < 4
Spanish Language Yes Yes
Assessment 
Perspective
Parents' Parents' Patients' Patients' Parents'
Legend: WHO – World Health Organization.Health and Quality of Life Outcomes 2005, 3:3 http://www.hqlo.com/content/3/1/3
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18]. The FAQ walking scale provides the most complete
assessment of functional walking abilities, especially at
the upper end of the scale [89].
In summary, there are few measures available for assess-
ing subjects less than 5 years of age and even fewer for sub-
jects less than 2 years of age. Most relevant measures are
available in self-complete format only. Preliminary rec-
ommendations for the NF1-CTD study were that PedsQL
be used as the generic health profile, HUI be the multi-
attribute preference-based measure of HRQL utility scores
for children age 5 years and older and that CHSCS-PS be
the measure for children age 2 through 4 years, ASK be the
measure of activity limitation, FAQ walking scale be the
measure of walking ability, and that a small feasibility
study of these instruments be completed with a conven-
ience sample.
Feasibility study
A pilot feasibility study surveyed 8 NF1 patients using
HUI and FAQ walking scale measures. Questionnaires
were completed by 6 NF1 patients and 3 parents. The
combined HUI and FAQ walking scale questions took
respondents an average of 13 minutes (range, 9–20 min-
utes) to complete. The patients were 11 to 50+ years old
and had health problems ranging from mild to severe.
One patient with tibial dysplasia and 2 patients with sco-
liosis were included.
HUI data were collected from 5 patients, 2 parents and
both the patient and parents in one case. Health problems
were reported in 7 of the 8 HUI3 attributes (vision,
speech, ambulation, dexterity, emotion, cognition, and
pain; no problems with hearing were reported). The
attributes associated with the most morbidity, as assessed
Table 3: Domains and Constructs of Forms for Two Pediatric Health Profile Systems
Instrument CHQ: Child Health Questionnaire PedsQL 4.0
Version Parent Forms (PF) Youth-Completion Form Parent Form for 
Infants & Toddlers
Child Forms (3 
versions: 5–7, 8–12, 
13–18 yrs)
Parent Forms (4 
versions: 2–4, 5–7, 8–
12, 13–18 yrs)
Domain Names 1. Physical functioning – 6 items.
- e.g., Child is greatly limited in performing all 
physical activities, including self-care, due to physical 
health.
2. Role (school and activities) limitations due to 
emotional.*
3. Role limitations due to behavioral problems* – 3 
items.
- e.g., Child is limited a lot in school work or 
activities with friends due to behavioral problems.
4. Role limitations due to physical problems – 2 
items.
- e.g., Child is greatly limited in school work or 
activities with friends due to physical health.
5. Bodily pain – 2 items.
- e.g., Child has extremely severe, frequent and 
limiting body pain.
6. General behavior – 6 items.
- e.g., Child very often exhibits aggressive, 
immature, delinquent behavior.
7. Mental health – 5 items.
- e.g., Child has feelings of anxiety and depression all 
the time.
8. Self-esteem – 6 items.
- e.g., Child is very dissatisfied with abilities, looks, 
family/peer relationships and life overall.
9. General health perceptions – 6 items.
- e.g., Parent believes child's health is poor and likely 
to get worse.
10.Change in health – 1 item.
- e.g., Child's health is much worse now than 1 year 
ago.
1. Physical 
Functioning.
2. Behavior 
(perception).
3. Growth & 
Development.
4. Pain.
5. Behavior (getting 
along).
6. Temperament & 
Mood.
7. General Health.
8. Change in Health.
1.. Physical Functioning – 8 items.
- hard to walk more than one block, hard to 
run, hard to do sports or exercises, hard to lift 
something heavy, hard to take a bath, hard to 
do chores around the house, hurt or ache, low 
energy.
2. Emotional Functioning – 5 items.
- feel afraid or scared, feel sad or blue, feel 
angry, trouble sleeping, worry about what will 
happen.
3. Social Functioning – 5 items.
- trouble getting around, other kids not 
wanting to be friends, teased, doing things 
other peers do, hard to keep up when playing 
with others.
4. School Functioning – 5 items.
- hard to concentrate, forget things, trouble 
keeping up with schoolwork, miss school 
because not well, miss school for doctor 
appointments.
*Role Emotional and Role Behavioral are separate scales in PF98 but combined into one in the PF50 and PF28.Health and Quality of Life Outcomes 2005, 3:3 http://www.hqlo.com/content/3/1/3
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using HUI3 single-attribute utility scores [60], were pain
(mean score = 0.81), speech (0.94), cognition (0.94), and
emotion (0.94). For the 7 patients having complete data,
5 had two or more HUI2 and HUI3 attributes at less than
full function. On the conventional utility scale in which
being dead = 0.00 and in perfect health = 1.00, the HUI3
scores ranged from 0.45 to 1.00. The mean HUI3 score,
0.73, is similar to the mean score of 0.77 for adults with
arthritis [90].
FAQ walking scale data were collected from 4 patients (1
of the 5 survey patients did not answer the question), 2
parents and both the patient and parents in one case. Five
patients were reported to be at Level 10 (walks, runs, and
climbs on level and uneven terrain and does stairs without
difficulty or assistance), one patient to be at Level 8 (walks
outside the home for community distances, is able to get
around on curbs and uneven terrain in addition to level
surfaces, but usually requires minimal assistance or super-
vision for safety), and one patient at Level 6 (walks more
than 15–50 ft. outside the home but usually uses a wheel-
chair or stroller for community distances or in congested
areas).
In summary, the feasibility study showed that the HUI
and FAQ walking scale questions were acceptable to
patients' families and that results, especially for HUI,
reflected the large variability in HRQL of the sample of
patients.
Choice of measures for illustrative study
No single measure will provide sufficient data to address
all the important study objectives. A set of measures is
required. The set of measures should provide complemen-
tary data of health status and preference-based scores of
HRQL. Redundancy in measurement is reduced, and
efficiency of measurement is increased, by selecting the
most comprehensive generic measures and then supple-
Table 4: Major Characteristics of Orthopedic-Specific Systems
Instrument PODCI ASK FAQ walking scale
Full Name Pediatric Outcomes
Data Collection
Instrument
Activities Scale for Kids Gillette Functional
Assessment Questionnaire:
Functional Walking Scale
Origin 1997 1996 1993
Measurement constructs Musculoskeletal outcomes Physical disability in terms of 
capacity or performance 
dimensions
Complete range of functional 
walking abilities
Age range (years) 2 – 18 2 – 18 2 +
# Items 108 30 1
# Domains; and Domains 8
Comorbidity, Upper Extremity & 
Physical Function, Transfers & 
Basic Mobility, Sports & Physical 
Function, Pain, Treatment 
Expectations, Happiness, 
Satisfaction with Symptoms.
9
Personal Care, Dressing, Eating & 
Drinking, Miscellaneous, Play, 
Locomotion, Standing Skills, Stairs, 
Transfers.
1
Walking.
Overall Score Yes, Global Function, mean of sub-
scales for domains 1 to 4 above
Yes, additive and not weighted Yes
Sub-scale Scores Yes, additive No No
Completion Time (minutes) 10 – 20 5 – 12 < 2
Spanish Language version No No No
Assessment Perspective Patient &/or Parent (Diagnostic, 
complications and aims section by 
clinician)
Patient ParentHealth and Quality of Life Outcomes 2005, 3:3 http://www.hqlo.com/content/3/1/3
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menting these measures with the most appropriate set of
specific measures.
It is recommended that HUI be selected as the compre-
hensive generic measure for ten reasons:
a) it includes both generic health profile and preference-
based scoring systems;
b) the preference-based scoring systems are well-vali-
dated;
c) it is the most comprehensive, compact and efficient of
these types of systems;
d) it includes many of the most important domains in the
context of NF1-CTD;
e) it is applicable for all people age 5 years and older;
f) well-developed data collection questionnaires are avail-
able to match the study design criteria;
g) HUI results facilitate integrating effects of morbidity
and mortality, and cost-utility economic evaluations;
h) it has been used successfully in a variety of studies of
musculoskeletal problems;
i) population norm data are available; and
j) a closely-related health status system, the CHSCS-PS, is
available to assess children 2 through 4 years of age.
The HUI will provide a broad set of measures for compar-
isons with other populations and for estimating HRQL on
a general scale such that dead = 0.00 and perfect health =
1.00. As a generic measure, HUI also has the ability to cap-
ture side effects and the effects of co-morbidities. How-
ever, these broad measures may not be responsive to small
but important changes in health status. Therefore, HUI
should be complemented by a set of instruments focused
on pediatric, orthopedic and walking issues.
The PedsQL 4.0, a pediatric generic health profile, should
also be included in the set of measures because:
a) it includes domains, social and school function, which
complement HUI and CHSCS-PS domains;
b) it is appropriate for children ages 2 through 18 years;
c) it is not overly burdensome in terms of data collection;
d) patient and parent assessment questionnaires are avail-
able; and
e) it can be interviewer-administered to facilitate data col-
lection by telephone, if necessary.
Two specific measures should also be part of the set of
instrumentation: the ASK and the FAQ walking scale. ASK
is an orthopedic-specific instrument which has been
shown to cover the most important domains in the con-
text of musculoskeletal disorders, including the impact of
limb lengthening surgery experienced by many children
with tibial dysplasia. ASK is also attractive because it pro-
vides overall summary scores for both performance and
capability measures, and is only moderately burdensome
to complete. Walking ability is one of the most important
aspects of health that is frequently compromised in NF1-
CTD patients, and the FAQ walking scale is the most com-
plete scale of functional walking ability currently available
and it only requires asking one question.
CHQ is not recommended because it does not add much
to the set of recommended measures and it is burdensome
to complete. PODCI is not recommended because it is
very burdensome to complete, it has been reported to
have major problems with "missing data", and the system
for collapsing questionnaire responses into summary
scores is not well validated.
Children ages 2 to 5 years of age should be assessed by
their parents using three questionnaires: the CHSCS-PS
(12 questions), the PedsQL (23 questions); and the FAQ
walking scale (1 question). It is expected that all three of
these questionnaires can be completed in an average of 15
minutes.
Children and adolescents ages 5 to 17 years of age should
be assessed by their parents using four questionnaires: the
HUI (15 questions), the PedsQL (23 questions), the FAQ
walking scale (1 question), and the ASK (30 questions).
These four questionnaires are expected to be completed in
an average of 20 to 30 minutes.
Children and adolescents older than 11 years should pro-
vide self-assessments using four questionnaires: the HUI
(15 questions), the PedsQL (23 questions), the FAQ walk-
ing scale (1 question), and the ASK (30 questions). On
average, it is expected that respondents will complete all
four questionnaires in 20 to 30 minutes.
Conclusions
This paper highlights reasons why patient-focused meas-
ures of FHS and HRQL should be considered important
tools in the field of orthopedic surgery. It has also noted
that there is increasing competition for scarce health-careHealth and Quality of Life Outcomes 2005, 3:3 http://www.hqlo.com/content/3/1/3
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resources, that allocation decisions about these resources
are being informed by evidence based on patient-focused
health measures, and that these measures are being under-
utilized by the orthopedic surgery community.
The orthopedic community faces numerous obstacles in
utilizing FHS and HRQL measures. One major obstacle is
that the multitude of existing measures makes it difficult
to decide which measures may be appropriate for a spe-
cific application. A second obstacle is that most of the
information about FHS and HRQL measures is not
reported in the orthopedic literature. A third obstacle is
that usually no one measure can capture all the important
aspects associated with a specific orthopedic issue. The
framework outlined in the paper provides guidance for
selecting appropriate FHS and HRQL measures. The
framework guides orthopedic investigators to combine
their basic study criteria, including objectives and clinical
context, with key criteria for FHS and HRQL measures
from the published literature.
The results in this paper identify some major sources of
information about health measures, identify some of the
most widely used measures of FHS and HRQL, and pro-
vide summaries of key characteristics for selected meas-
ures in three major taxonomical classes: generic
preference-based multi-attribute systems; generic pediat-
ric health profile systems; and orthopedic-specific sys-
tems. It is clear that there are many important differences
among measures both within and across taxonomical
classes. All measures are not equal. There are sound factors
for making judgements about which measures are most
appropriate for a given application. A process of appraisal
and elimination was used to select one measure from each
taxonomical class for inclusion in the NF1-CTD study
illustrative example, and a pilot study of the most readily
available selected measures confirmed the feasibility of
their use in a small sample of NF1-CTD patients.
The paper shows that a set of relevant, valid, reliable,
responsive and practical patient-focused health measures
for use in an orthopedic study can be readily identified
and selected from the published literature and informa-
tion available on the worldwide web. We encourage
orthopedic researchers to use the framework to identify
and select appropriate patient-focused health measures in
their future studies.
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